Staphlococcus aureus: susceptibility to antibacterial drugs and rate of MRSA

O. V. Plekhanova (Dniepropetrovsk, Ukraine)

Source: Annual Congress 2006 - Hospital-acquired pneumonia: from inflammation to treatment
Session: Hospital-acquired pneumonia: from inflammation to treatment
Session type: Poster Discussion
Number: 4514
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
O. V. Plekhanova (Dniepropetrovsk, Ukraine). Staphlococcus aureus: susceptibility to antibacterial drugs and rate of MRSA. Eur Respir J 2006; 28: Suppl. 50, 4514

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Mechanisms of acquisition of resistance in Staphylococcus aureus
Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen?
Year: 2006


Treatment challenges in methicillin resistant Staphylococcus aureus infections
Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen?
Year: 2006


Vancomycin MICs for respiratory isolates of community-associated MRSA and hospital-associated MRSA
Source: Annual Congress 2007 - Pulmonary infections in the immunocompetent and immunocompromised host
Year: 2007


Predictive factors for methicillin-resistant Staphylococcus aureus (MRSA) infection in a MRSA screening protocol.
Source: International Congress 2018 – Difficult-to-treat respiratory infections
Year: 2018


Clinical outcomes of patients with hospital-acquired pneumonia due to community-associated methicillin resistant staphylococcus aureus (CA-MRSA)
Source: Eur Respir J 2007; 30: Suppl. 51, 407s
Year: 2007

The efficacies of macrolides in a murine model of methicillin-resistant staphylococcus aureus hematogenous pulmonary infection
Source: Eur Respir J 2002; 20: Suppl. 38, 357s
Year: 2002

What is MRSA?
Source: Eur Respir J 2009; 34: 1190-1196
Year: 2009



Cell wall deficiency: a novel mechanism for methicillin resistance in Staphylococcus aureus
Source: Eur Respir J 2005; 26: Suppl. 49, 94s
Year: 2005

Molecular epidemiology and antimicrobial resistance of methicillin-resistant staphylococcus aureus isolated from nasal swab at intensive care unit
Source: Annual Congress 2008 - Features of hospital-acquired pneumonia, ventilator-associated pneumonia and infection with other pathogens
Year: 2008


Increasing global resistance to penicillin, macrolides and other antimicrobials among isolates of Streptococcus pneumoniae: susceptibility data from three years of the PROTEKT surveillance study
Source: Eur Respir J 2003; 22: Suppl. 45, 486s
Year: 2003

Community-associated methicillin-resistant staphylococcus aureus (CA-MRSA) as a cause of hospital-acquired pneumonia (HAP)
Source: Eur Respir J 2007; 30: Suppl. 51, 410s
Year: 2007

Antibiotic susceptibility patterns of respiratory strains of Staphylococcus aureus in a Turkish university hospital
Source: Eur Respir J 2003; 22: Suppl. 45, 148s
Year: 2003

Changes in susceptibility to antibiotics staphylococcus aureus under effect of dissolved ozone
Source: Annual Congress 2009 - Models of chronic airways disease and therapy
Year: 2009

CusS-cusR mediate carbapenem-resistant Klebsiella pneumoniae resistant to tigecycline.
Source: International Congress 2019 – Clinical challenges in respiratory infection
Year: 2019

Staphylococcus aureus sensitivity changes to antibiotics under the influence of dissolved ozone
Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis
Year: 2011

Evolution of tetracycline resistant S. aureus in hypoxia
Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases
Year: 2021


Prevention of MRSA pneumonia by oral vancomycin decontamination: a randomised trial
Source: Eur Respir J 2004; 23: 921-926
Year: 2004



Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae
Source: Eur Respir J 2006; 27: 1020-1025
Year: 2006



Long-term, low-dose azithromycin treatment reduces the prevalence of staphylococcus aureus, but selects for macrolide resistance in Danish CF-patients
Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects
Year: 2007